Further studies that throw light upon the regulation of Fibulin-5 expression may offer innovative strategies to develop potential pharmacological or biological agents for the treatment of NSCLC with IDH1 mutation. This evidence concerns the gene IDH1 and non-small cell lung carcinoma.